Our cytotoxic drug bundles offer a highly versatile design, enabling the rapid assembly and production of various drug bundles to fit diverse conjugation needs. This facilitates the customized development and scalable manufacturing of ADC therapeutics.
In addition to generating drug bundles carrying a single cytotoxic payload, our platform allows for the rapid and efficient production of dual-cytotoxic drug bundles. This breakthrough overcomes a key technical barrier in ADC development by enabling the conjugation of two distinct payloads, offering new hope for the treatment of drug-resistant and heterogeneous tumors.
Below are the diverse combinations of dual-drug cytotoxic drug bundles we currently produce:
We are committed to advancing the application of our drug bundle platform. Regardless of the desired payload combinations, we welcome partners to explore collaboration opportunities and licensing arrangements through various business models.
With our innovative technology, we strive to continuously overcome the limitations of ADC development and drive new breakthroughs in the field.